Taft Intellectual Property partner Richard Ruzich will be a speaker at the American Conference Institute (ACI) Paragraph IV Disputes Conference on Oct. 16 at the Hyatt Regency McCormick Place in Chicago. The conference will bring together pharmaceutical patent litigators for brand name and generic drug companies to receive the latest insights on Hatch-Waxman litigation. Ruzich will speak during the session “Risky Business: At-Risk Launch Scenarios from Both the Brand and Generic Point of View,” discussing generic perspectives on cost-benefit analysis for an at-risk launch and brand perspectives on ways to prevent and respond to an at-risk launch scenario.

For more information or to register, click here.

Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in ANDA litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney, and a frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilar sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development, and through to market entry, including at-risk launches.